

21 March 2026

Diagnosis of Alzheimer’s Disease

1. Where, if at all, does the Trust carry out lumbar punctures (cerebrospinal fluid) for diagnosing patients with Alzheimer’s disease?

	Yes / No
Lumbar punctures carried out within the Trust itself	Yes
Lumbar punctures referred elsewhere and carried out external to the Trust	No
Trust does not carry out lumbar punctures to diagnose Alzheimer’s Disease	No

2. Please provide a list of the full names of other Trusts or other organisations to which the Trust refers patients for lumbar puncture procedures in the diagnosis of Alzheimer’s disease.

Full name of organisation(s)
Not applicable

3. How many lumbar puncture procedures to test for Alzheimer’s disease were performed in the last three-month period for which data are available?

	Number of procedures
Number of lumbar punctures	12

21 March 2026

4. Where, if at all, does the Health and Social Care Board carry out Blood Biomarker (BBM) tests for diagnosing NHS patients with Alzheimer’s disease?

	Yes / No
Pathology laboratory within the Trust	No
Pathology laboratory external to the Trust	No
Trust does not test for BBMs to diagnose Alzheimer’s Disease	Yes

5. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers Blood Biomarker tests for the diagnosis of Alzheimer’s disease for NHS patients.

Full name of Trust or organisation(s)
Not applicable

6. Please provide the number of BBM tests for Alzheimer’s Disease conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory.

	Number of Tests TOTAL	Number of Tests NHS Patients	Number of Tests Private Sector
Number of Blood Biomarker tests	0	0	0

21 March 2026

7. Which of the following biomarker tests were used to detect Alzheimer's disease?

	Yes / No
pTau181 immunoassay tests	Yes – in CSF
pTau217 immunoassay tests	No

8. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers samples for pTau181 and pTau217 immunoassay testing for Alzheimer's disease?

Full name of Trust or organisation(s)
Not applicable

9. How many pTau181 immunoassay tests were conducted to test for Alzheimer's disease in the last three-months?

	Number of Tests TOTAL	Number of Tests NHS Patients	Number of Tests Private Sector
Number of pTau181 tests	If blood - 0	If blood - 0	If blood - 0

21 March 2026

10. Is pTau181 testing for Alzheimer’s disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau181 Testing associated with clinical trial activity	No

11. How many pTau181 immunoassay tests were conducted for Alzheimer's disease as part of a clinical trial?

Number of pTau181 tests	If blood - 0
-------------------------	--------------

12. How many pTau217 immunoassay tests were conducted to test for Alzheimer's disease in the last three-months?

	Number of Tests TOTAL	Number of Tests NHS Patients	Number of Tests Private Sector
Number of pTau217 tests	0	0	0

13. Is pTau217 testing for Alzheimer’s disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau217 Testing associated with clinical trial activity	No

21 March 2026

14. How many pTau217 immunoassay tests were conducted for Alzheimer's disease as part of a clinical trial?

Number of pTau217 tests	0
-------------------------	---

15. Does your organisation participate in any of the following clinical trials?

	Yes / No
READ-OUT	Awaiting approvals
ADAPT	Not as yet, no
Other(s) please specify below:	

16. Which of the following metrics are used by the Trust to measure Blood Biomarker in the diagnosis of Alzheimer's disease?

	Yes / No
Number of tests	N/A
Number of kits	N/A
Number of runs	N/A
Number of units	N/A
Number of patients	N/A